NEXTCURE INC

Simcere Zaiming sells 30,000 NEXTCURE shares – a strategic liquidity move that signals confidence and fuels investor curiosity about the biotech’s future.

ADAR1 Capital’s cautious buying spree at $5 each signals bullish confidence in NextCure’s immunomedicine pipeline, potentially fueling a short‑term rally and boosting cash runway for future trials.